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Abstract
Ovarian cancer is the most lethal of all gynecologic malignancies because women commonly present with advanced
stage disease and develop chemotherapy refractory tumors. While cytoreductive surgery followed by platinum based
chemotherapy are initially effective, ovarian tumors have a high propensity to recur highlighting the distinct need for
novel therapeutics to improve outcomes for affected women. The Notch signaling pathway plays an established role in
embryologic development and deregulation of this signaling cascade has been linked to many cancers. Recent
genomic profiling of serous ovarian carcinoma revealed that Notch pathway alterations are among the most prevalent
detected genomic changes. A growing body of scientific literature has confirmed heightened Notch signaling activity
in ovarian carcinoma, and has utilized in vitro and in vivo models to suggest that targeting this pathway with gamma
secretase inhibitors (GSIs) leads to anti-tumor effects. While it is currently unknown if Notch pathway inhibition can offer
clinical benefit to women with ovarian cancer, several GSIs are currently in phase I and II trials across many disease sites
including ovary. This review will provide background on Notch pathway function and will focus on the pre-clinical
literature that links altered Notch signaling to ovarian cancer progression.
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Background
Ovarian cancer represents the most lethal gynecologic
malignancy in the United States. In 2014 alone, ap-
proximately 22,000 women are estimated to be diag-
nosed with ovarian cancer and more than 14,000 deaths
attributed to the disease are projected to occur [1]. This
high mortality is explained in part by the advanced dis-
ease stage at the time of diagnosis with approximately
75% of the patients presenting with stage III - IV disease
[2]. Therapeutic strategies include cytoreductive surgery
followed by six cycles of platinum and taxane based
chemotherapy [3,4]. Despite the fact that the majority of
patients achieve complete clinical remission following this
treatment regimen, the prognosis of ovarian cancer re-
mains unfavorable with a 5-year survival rate of approxi-
mately 50% [4]. This poor outcome is mainly attributed to
the development of recurrent disease that is often resistant
to chemotherapy [5,6]. Treatment options for recurrent
ovarian cancer are currently limited and not curative, war-
ranting the development of novel therapeutic strategies.
Epithelial ovarian malignancies comprise heterogeneous
tumors, both on a cellular and a molecular level. A re-
cently developed dualistic model divides the different
ovarian cancer subtypes into type I and type II carcinomas
[7]. Type I tumors comprise low-grade serous, low-grade
endometrioid, clear cell and mucinous ovarian cancers.
They are characterized by indolent, genetically stable tu-
mors that arise from a precursor lesion, often present
at an early stage and are relatively resistant to cytotoxic
therapy. In contrast, the more prevalent type II tumors are
highly aggressive, present at an advanced stage, typically
harbor TP53 mutations that lead to genetic instability, and
are initially more sensitive to chemotherapeutic agents.
While high-grade serous carcinomas account for the vast
majority of type II ovarian cancers, other subtypes in-
clude high-grade endometrioid ovarian carcinoma and
carcinosarcomas [8,9]. In recent years, multiple genetic
and epigenetic abnormalities as well as changes in mo-
lecular pathways have been identified that are often
characteristic for specific histologic subtypes [10,11].
Therapeutic targeting of the molecular aberrations and
cellular signaling pathways involved in tumor progres-
sion may provide novel treatment options for women
with recurrent ovarian cancer. This review will focus
on the role of the Notch signaling cascade in high-
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http://www.ovarianresearch.com/content/7/1/95grade serous ovarian cancer and the potential thera-
peutic effectiveness of Notch pathway inhibition in this
disease.
The Notch signaling pathway
Functions of Notch signaling
The evolutionary conserved Notch pathway was first dis-
covered in Drosophila a century ago, when flies with a
mutation in the Notch gene were found to have wing de-
formities [12]. The functional significance of the Notch
signaling cascade has been well established in neural de-
velopment [13,14] and has since been established in mul-
tiple cellular processes, during embryonic development
and in self-renewing adult tissues [15,16]. The Notch
pathway functions through cell-to-cell contact and is in-
volved in the regulation of proliferation, differentiation
and apoptosis, depending on the cellular context [17,18].
In adult tissues, Notch signaling acts to control tissue
homeostasis and stem cell maintenance.
Notch receptors and ligands
Thus far, four Notch receptors (Notch1-4) and five li-
gands have been identified in mammals. Three ligands
belong to the Delta-like family (Dll1, 3 and 4) and two li-
gands (Jagged1 (Jag1) and Jagged2 (Jag2)) are Serrate-
like [19-23]. Notch receptors as well as their ligands are
single-pass transmembrane proteins with extracellular
domains that consist of multiple epidermal growth factor
(EGF)-like repeats [24,25]. The receptors are synthesized
as inactive precursors in the endoplasmic reticulum that
are proteolytically cleaved by furin-like convertases in
the trans-Golgi compartment [26]. This first cleavage,
termed S1, results in an extracellular N-terminal frag-
ment and a transmembrane C-terminal fragment that
also includes the Notch intracellular domain (NICD). Fi-
nally, non-covalent binding between the two fragments
forms the mature Notch heterodimeric receptor [27]
(Figure 1). During the process of Notch receptor synthe-
sis, the extracellular fragment is glycosylated by Fringe
Figure 1 The Notch signaling cascade is activated by cell-cell interaction.
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between the receptor and its ligands [28,29].
Signaling cascade
As shown in Figure 1, Notch signaling is activated by a
receptor-ligand binding between two neighboring cells,
leading to a conformational change of the Notch recep-
tor and exposure of a cleavage site (S2) in its extracellu-
lar domain [30,31]. S2 cleavage by A Disintegrin And
Metalloprotease (ADAM)10 or 17 produces an inter-
mediate transmembrane fragment termed NEXT (Notch
extracellular truncation) which is accessible to gamma-
secretase for S3 cleavage [32]. The gamma-secretase
complex consists of four subunits: the catalytic subunit
presenilin, nicastrin, APH-1 and PEN-2 [33]. S3 cleavage
by gamma-secretase leads to release of the NICD, which
translocates to the nucleus and binds to the DNA bound
CBF-1/Su(H)/Lag-1 protein complex (CSL, also known
as RBP-jκ) that constitutively represses transcription in
the absence of NICD [34,35]. The NICD displaces a co-
repressor complex from CSL and recruits co-activators
such as Mastermind-like 1 (MAML1), allowing the tran-
scription of Notch target genes [34,36].
Notch target genes
The most well-known Notch target genes are transcrip-
tion factors of the Hairy/Enhancer of Split (Hes) and
Hes-related (Hey) families [37]. Hes and Hey members
are helix-loop-helix proteins, forming homo-or heterodi-
mers that regulate transcription of genes involved in cell
fate determination [37-39]. Other Notch pathway targets
include cell cycle regulators cyclin D1 and p21, NF-κB
family members, c-Myc and Deltex [40-43].
Crosstalk with other signaling pathways
The Notch pathway is part of a complex network of de-
velopmental signaling pathways that also includes the
Hedgehog, Wnt, receptor tyrosine kinases (RTK), trans-
forming growth factor-β (TGF-β) and Janus kinase/signal
transducers and activators of transcription (Jak/STAT)
pathways [44,45]. The Notch pathway has also been im-
plicated as interacting with the EGFR/HER2 receptor
tyrosine kinase family, as well as phosphatidylinositol
3-kinase/AKT/mTOR signaling cascade, two central
growth pathways in the physiologic and neoplastic set-
ting [46]. Although integration of Notch signaling with
signals from other pathways has been a focus of investi-
gation, the exact mechanisms of this crosstalk remain
largely unknown. The interaction of Notch signaling
with other pathways highly depends on the cellular context,
and differs from one cellular environment to another. For
example, the Notch and Wnt pathways were found to co-
operate in maintaining undifferentiated hematopoietic stem
cells [47], whereas an antagonistic interaction between Wnt
and Notch has been reported in Drosophila development
[48]. Similarly, opposed functions in distinct cellular con-
texts have been reported for the Notch and Ras pathways.
Notch signaling was shown to complement the Ras path-
way during Drosophila eye development [49], while inhib-
ition of the Ras pathway by Notch signaling has been
demonstrated in C. elegans hermaphrodite vulval develop-
ment [50,51]. Activation of Sonic Hedgehog (Shh) led to
upregulation of Notch signaling and determination of ar-
terial cell fate in zebrafish [52], and induction of Shh has
been observed in murine somatic and human embryonic
stem cells following Notch receptor activation [53]. The
phosphatidylinositol 3-kinase (PI3K)-AKT and Notch sig-
naling cascades were found to interact agonistically during
murine hematopoietic stem cell differentiation and in a
variety of human cell types including T-cells and neurons
[54,55]. Negative crosstalk between the EGFR and Notch
pathways has been described in Drosophila wing develop-
ment [56,57], while Notch signaling was shown to activate
Her2 (ERBB2) in human embryonic kidney cells [58].
Notch signaling in cancer
Oncogenic Notch signaling was first described in T-cell
acute lymphoblastic leukemia (T-ALL), in which a
chromosomal translocation event generates a constitutively
active variant of Notch1 [59]. Later studies have shown
that Notch1 activating mutations occur in the majority of
T-ALLs [60]. Deregulation of Notch receptors, ligands or
targets has since been described in a variety of solid and
hematological tumors including breast [61,62] pancreatic
[63], brain [64], lung [65], ovarian [11], head and neck [66]
and colorectal [67] cancer, as well as leukemia [60,68],
lymphomas [69,70] and multiple myeloma [71]. While
these and other studies demonstrate Notch pathway in-
volvement in tumor initiation and progression, tumor sup-
pressive roles of Notch signaling have also been reported
[72,73]. Most notably, Notch functions as a tumor suppres-
sor in the skin, and loss-of-function mutations in Notch re-
ceptors have been identified in cutaneous squamous cell
carcinoma [74,75]. Although little is known about the mech-
anisms behind these contradictory actions of the Notch
pathway in cancer, it is generally assumed that the various
outcomes of Notch signaling depend on interactions with
the microenvironment and crosstalk with other signaling
pathways [72].
Notch signaling in serous ovarian cancer
In ovarian cancer, a role for Notch signaling was first
discovered in two studies aimed at identifying potential
diagnostic markers of epithelial ovarian cancer. Gene ex-
pression of human ovarian cancer samples or cell lines
was evaluated and compared to normal ovarian surface
epithelium samples or cell lines, respectively [76,77].
One study reported upregulation of the Notch3 gene in
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reported increased Jag2 gene expression in ovarian cancer
cell lines compared with benign controls [77]. Subse-
quently, Park et al. used a single nucleotide polymorphism
(SNP) array to analyze DNA copy number alterations in
high-grade serous ovarian carcinomas and identified an
amplicon corresponding to the Notch3 locus in 20% of
cases. Notch3 gene amplification correlated with Notch3
protein overexpression, as determined by fluorescent in
situ hybridization and immunohistochemistry (IHC) [78].
These results were confirmed by others, who demon-
strated amplification of the Notch3 gene using a SNP array
in 21% of analyzed ovarian cancers [79]. Moreover, recent
large-scale genomic and epigenomic analyses of high-
grade serous ovarian carcinomas by The Cancer Genome
Atlas (TCGA) Network revealed altered Notch signaling
in 22% of cases with alterations in Notch3 occurring in
50% of those cases [11]. In a study of Notch ligands, Jag1
was shown to be the most highly expressed ligand in both
ovarian cancer cells and surrounding peritoneal mesothe-
lial cells with interaction of Jag1 and Notch3 resulting in
activation of the signaling cascade and promotion of cell
proliferation and adhesion [80]. In addition, Pbx1 and
DLGAP5 have been identified as direct target genes of
Notch3 in ovarian cancer, and knockdown of either target
with shRNAs led to reduced cell proliferation and, in the
case of Pbx1 knockdown, impaired tumor formation
[81,82]. More recently, the TCGA data generated from
488 ovarian cancer patients were used to analyze epigen-
etic changes of genes of the Notch superfamily. Inverse
correlations were found between DNA methylation and
expression of the Notch pathway target genes CCND1 and
PPARG and the Notch-interacting gene RUNX1.A d d -
itionally, an inverse correlation in expression was estab-
lished between CCND1, PPARG and RUNX1 and specific
miRNAs that regulate each of those genes. Subsequent
survival analyses revealed significantly poorer overall sur-
vival rates of patients with high CCND1, PPARG and
RUNX1 gene expression and low methylation or low levels
of the relevant miRNAs compared with patients with
low gene expression and high methylation or high miRNA
levels [83]. Furthermore, several groups have linked Notch3
expression to the clinical prognosis of ovarian cancer. Using
quantitative reverse transcription polymerase chain reaction
(RT-PCR) and IHC, Jung et al. o b s e r v e de l e v a t e dm R N A
levels of Notch3, Jag1 and Jag2 as well as higher Notch3
and Jag2 protein expression in serous ovarian cancer
samples as compared to benign controls. High Notch3
mRNA expression correlated significantly with worse
overall survival and clinical chemoresistance, and Notch3
protein overexpression was significantly associated with
the prognostic parameters advanced stage disease, lymph
node metastases and distant metastases [84]. Moreover, el-
evated nuclear Notch3 immunostaining has been found in
recurrent serous ovarian carcinoma specimens as com-
pared to primary ovarian cancer samples from the same
patients. A significant association between high Notch3
mRNA or nuclear Notch3 protein levels and worse overall
and progression-free survival rates was also described
[85,86]. Ectopic expression of Notch3 following trans-
duction with a Notch3 intracellular domain (NICD3) in
ovarian surface epithelium and low-grade serous ovarian
cancer cell lines with low endogenous Notch3 expression
led to increased resistance to carboplatin in vitro.I n v e r s e l y ,
shRNA-mediated knockdown of Notch3 in OVCAR3 cells
resulted in higher sensitivity to carboplatin, compared with
OVCAR3 cells transduced with a non-specific control
shRNA [85].
The role of Notch1 in ovarian cancer was first studied by
Hopfer et al., [87] who evaluated mRNA expression of
Notch pathway members in ovarian adenocarcinomas, bor-
derline tumors and adenomas and demonstrated more fre-
quent expression of Jag2 and DLL1 in adenocarcinomas as
compared to adenomas. Although quantitative RT-PCR
and Western blot analyses revealed similar Notch1 expres-
sion levels in ovarian adenocarcinomas and adenomas,
stable transfection of A2780 ovarian cancer cells with the
intracellular domain of Notch1 (NICD1) increased cell
proliferation and enhanced colony-formation capacity, sug-
gesting a role for Notch1 signaling in ovarian tumor
growth [87]. Analyses of the NICD1 protein by other inves-
tigators revealed high NICD1 levels in OVCAR3, SKOV3
and CaOV3 cell lines. Additionally, NICD1 was expressed
in 76% of primary human serous ovarian cancer samples,
as assessed by Western blotting. Subsequent siRNA down-
regulation of NICD1 in all three ovarian cancer cell lines
resulted in inhibition of cell proliferation [88]. Results ob-
tained from PCR, immunoblotting or functional studies of
Notch1 have been easily interpreted. In contrast, IHC ana-
lyses of Notch1 expression in ovarian cancer have pro-
duced variable results. Wang and colleagues used IHC to
study Notch1 levels in ovarian cancer specimens of vari-
ous histological grades as well as patient-matched contra-
lateral benign ovarian samples and normal ovarian tissues.
Notch1 immunostaining was observed in 95% of ana-
lyzed serous ovarian cancer specimens versus 8% and
6% of matched benign controls and normal ovarian
samples, respectively. Notch1 immunostaining was pre-
dominantly found in the cell membrane and cytoplasm.
Positivity scores correlated with histological grade and
clinical disease stage, and the IHC findings were con-
firmed by Western blotting and quantitative RT-PCR
[89]. An IHC protocol was recently developed to detect
the gamma-secretase cleaved NICD1. In contrast to the
findings of the full-length Notch1 IHC studies, NICD1
was not expressed in any of the 147 analyzed ovarian can-
cer specimens although a subset of samples from other
cancer types showed nuclear NICD1 immunostaining with
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ous ovarian tumors by others detected expression of
Notch1, Jag1 and Dll1 in both cytoplasm and nucleus, and
the observed Notch1 protein levels correlated significantly
with metastasis in this small cohort [91].
Notch signaling in serous ovarian cancer stem cells
A few investigations have shown elevated Notch levels in
recurrent or chemoresistant ovarian cancer. In ovarian
cancer and many other malignancies, the development of
recurrent disease has been attributed, at least in part, to a
tumorigenic and chemotherapy resistant sub-population
of cancer cells called tumor-initiating or cancer stem cells
(CSCs) [92-94]. Consistent with this hypothesis, increased
expression of CSC markers and enrichment of the side
population (cells showing increased efflux of Hoechst dye
as identified by flow cytometry, reviewed in Foster et al.,
[95]) have been observed in ovarian cancer samples fol-
lowing platinum based chemotherapy, compared with
chemotherapy naive cells [96,97]. Similarly, increased re-
sistance to cisplatin and paclitaxel has been demonstrated
in sphere forming primary serous ovarian cancer cells,
cultured under stem cell-selective conditions, compared
with the same cells cultured under differentiating condi-
tions. These spheroid ovarian CSCs also showed elevated
levels of the CSC marker proteins CD44 and CD117 as
well as an increase in mRNA levels of Notch1 and other
stem cell genes, compared with differentiated cells and
parental bulk tumor cells [98]. Retrovirus-mediated over-
expression of the Notch3 intracellular domain (NICD3) in
ovarian surface epithelium and low-grade serous ovarian
cancer cell lines with low endogenous Notch3 levels led to
upregulation of the stem cell associated genes Nanog and
Oct4, further suggesting a role of the Notch pathway in
CSC function [85]. Furthermore, gene microarray analyses
of serous ovarian cancer side population cells from ascites
samples showed upregulation of three genes involved in
Notch signaling, compared with main population cells.
These genes, ADAM19, FPTG and ST3GAL6,w e r ea l s o
found to be overexpressed in recurrent ovarian cancer
specimens, compared with matched primary samples
[99]. Supporting these findings, Steg and colleagues
have reported increased transcript levels of stem cell
pathway genes, including the Notch pathway member
presenilin 2 (PSEN2), in recurrent ovarian cancer sam-
ples compared with matched primary tumors [96]. Col-
lectively, these studies provide evidence suggesting that
Notch signaling is enhanced in ovarian CSCs, as com-
pared to tumor bulk cells.
Notch signaling and epithelial-to-mesenchymal transition in
serous ovarian cancer
In addition to its role in CSCs, the Notch pathway has
been implicated in epithelial-to-mesenchymal transition
(EMT) and may thereby promote tumor invasiveness and
metastasis [100]. The process of EMT has been associ-
ated with chemoresistance and stem cell-like character-
istics in several cancers [101], including ovarian cancer
[102-104]. A recent study has demonstrated that over-
expression of NICD3 in OVCA429 serous ovarian can-
cer cells induces EMT, as confirmed by a fibroblast-like
cell morphology as well as upregulation of the mesenchy-
mal markers Slug, Snail and smooth muscle α-actin and
down regulation of the epithelial marker E-cadherin. The
OVCA429/NICD3 cells showed increased resistance to
carboplatin-induced apoptosis compared with OVCA429
control cells [105]. Although further investigation of the
role of the Notch pathway in ovarian EMT is needed,
these findings suggest that activation of Notch can induce
EMT in serous ovarian carcinomas.
Notch signaling and angiogenesis in serous ovarian cancer
While Notch signaling has been linked extensively to
tumor angiogenesis [106-108] in many malignancies,
few studies have described a similar role of the pathway
in ovarian tumor angiogenesis [109,110]. Lu and col-
leagues investigated gene expression differences be-
tween endothelial cells from high-grade serous ovarian
carcinomas and endothelial cells from benign ovaries
using gene microarrays. Overexpression of 23 genes was
found in ovarian tumor endothelial cells as compared to
benign ovarian endothelial cells. Among these upregulated
genes was Jagged1, and silencing of this gene with a siRNA
decreased tube formation and migration of endothelial
cells [109]. Other investigators observed Dll4 overexpres-
sion in tumor and endothelium in 72% of ovarian cancer
samples analyzed by IHC, and increased Dll4 levels were
associated with worse overall survival when compared to
samples with low Dll4 expression. When DLL4 was si-
lenced in vivo using nanoparticle delivery of a DLL4 spe-
cific siRNA to mice harboring A2780 or SKOV3ip1 cell
line derived xenografts, the targeting of both tumor cells
and tumor-associated mouse endothelial cells inhibited
tumor growth and deregulated angiogenesis. Moreover,
tumor growth was further inhibited when the vascular
endothelial growth factor inhibitor bevacizumab was
added to this treatment regimen [110] suggesting synergy
between anti-VEGF treatment and Dll4 targeting. In sum-
mary, the described studies provide evidence to suggest
that the Notch pathway is not only involved in epithelial
ovarian tumor growth, but also plays a role in endothelial
cell function and angiogenesis of serous ovarian tumors.
Therapeutic targeting of the Notch pathway in serous
ovarian cancer
The growing body of evidence regarding the role of
Notch signaling in cancer has led to the development of
different Notch pathway inhibitors, a number of which
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the pathway can be targeted, and established classes of
inhibitors include monoclonal antibodies against Notch
ligands or receptors, receptor decoys, gamma-secretase
inhibitors (GSIs), peptides that block the nuclear tran-
scriptional complex, and natural compounds [111,112].
GSIs are the most widely studied Notch pathway target-
ing agents. A variety of GSIs with distinct chemical
structures but similar biological activity have been devel-
oped and each [113] inhibits signaling through all four
Notch paralogs by preventing formation of the active
NICD. Pre-clinical studies in a variety of cancers have
shown inhibition of tumor growth or cell proliferation
by GSIs [114-118]. In early phase clinical trials of GSIs,
promising anti-tumor effects in several solid malignan-
cies have been observed [119-122] despite dose-limiting
toxicities evidenced mainly by gastrointestinal events.
Over 40 clinical trials investigating the efficacy of GSI
therapy in solid or hematologic cancers are ongoing or
have recently been completed (see Table 1 for current
list of ongoing trials). A subset of these trials use GSI in
combination with standard chemotherapy or other tar-
geting agents (([112]) https://clinicaltrials.gov/).
Preclinical studies of Notch inhibition with GSI in serous
ovarian cancer: in vitro models
Several groups have studied the in vitro effectiveness of
GSIs in serous ovarian cancer. A reduction of cell pro-
liferation and induction of apoptosis have been re-
ported in OVCAR3 and A2780 ovarian cancer cell lines
following administration of the compound GSI-1, com-
pared with DMSO controls [78]. The same GSI was
used by others who showed decreased cell proliferation
post-treatment in A2780 and cisplatin resistant KFr13
serous ovarian cancer cell lines which both express high
levels of NICD3 [86]. Moreover, it was shown that treat-
ment of A2780 cells with the GSI DAPT decreased cell
proliferation in a dose- and time-dependent manner, inhib-
ited colony formation and induced cell cycle arrest and
apoptosis while reducing Notch1 and Hes1 mRNA and
protein levels [123]. In contrast with these findings, a recent
study showed unchanged proliferation rates of OVCAR3,
Table 1 Ongoing phase I and phase II trials of therapies targeting the Notch pathway
Drug Target ClinicalTrials.gov
identifier
n Delivery Disease site Monotherapy or combination
MK-0752 γ-secretase NCT01098344 60 Oral Unresectable pancreatic
cancer
Combination with gemcitabine
RO4929097 γ-secretase NCT01071564 46 Oral Unresectable breast cancer Combination with vismodegib
RO4929097 γ-secretase NCT01238133 14 Oral Neoadjuvant breast cancer Combination with carboplatin
and paclitaxel
RO4929097 γ-secretase NCT01122901 60 Oral Glioblastoma Monotherapy
RO4929097 γ-secretase NCT01151449 30 Oral Breast cancer Monotherapy
NCT01120275 24 Melanoma
NCT01232829 21 Pancraetic cancer
RO4929097 γ-secretase NCT01119599 34 Oral Glioblastoma Combination with radiation
therapy and temozolomide
RO4929097 γ-secretase NCT01193881 39 Oral Lung cancer Combination with erlotinib
RO4929097 γ-secretase NCT01158274 30 Oral Refractory solid tumors Combination with capecitabine
RO4929097 γ-secretase NCT01141569 5 Oral Renal cell cancer Monotherapy
RO4929097 γ-secretase NCT01189240 13 Oral Glioblastoma Combination with bevacizumab
RO4929097 γ-secretase NCT01200810 78 Oral Refractory prostate cancer Combination with bicalutamide
RO4929097 γ-secretase NCT01175343 37 Oral Refractory ovarian, fallopian
tube or peritoneal cancer
Monotherapy
BMS-906024 γ-secretase NCT01653470 95 IV Advanced/metastatic solid
tumors
Combination with weekly paclitaxel;
5-FU and irinotecan; carboplatinand
paclitaxel
BMS-906024 γ-secretase NCT01292655 110 IV Advanced/metastatic solid
tumors
Monotherapy
BMS-906024 γ-secretase NCT01363817 42 IV T-cell leukemia or lymphoma Monotherapy
BMS-986115 γ-secretase NCT01986218 40 Oral Advanced/metastatic solid tumors Monotherapy
PF-03084014 γ-secretase NCT01981551 17 Oral Desmoid tumors Monoterapy
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Drug Target ClinicalTrials.gov identifier n Delivery Disease site Monotherapy or combination CR (%) PR (%) SD (%)
MK-0752 γ-secretase NCT00106145 [120] 103 Oral Solid tumors Monotherapy 1 (1) 0 (0) 10 (10)
MK-0752 γ-secretase NCT00645333 [121] 30 Oral Breast cancer Combination with docetaxel 0 (0) 11 (42) 9 (34)
MK-0752 γ-secretase NCT00572182 [126] 23 Oral Refractory Pediatric CNS cancer Monotherapy 0 (0) 0 (0) 2 (9)
RO4929097 γ-secretase NCT01198184 [127] 17 Oral Solid tumors Combination with temsirolimus 0 (0) 0 (0) 11 (73)
RO4929097 γ-secretase NCT01145456 [119] 18 Oral Solid tumors Combination with gemcitabine 0 (0) 1 (6) 4 (22)
RO4929097 γ-secretase NCT01131234 [128] 20 Oral Solid Tumors Combination with cediranib 0 (0) 1 (5) 11 (55)
RO4929097 γ-secretase NCT01116687 [129] 33 Oral Metastatic colorectal cancer Monotherapy 0 (0) 0 (0) 6 (18)
RO4929097 γ-secretase NCT01232829 [130] 12 Oral Refractory pancreatic cancer Monotherapy 0 (0) 0 (0) 3 (25)
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5SKOV3 and several other ovarian cancer cell lines following
treatment with the GSIs Compound E, DAPT or dibenza-
zepine (DBZ) [94].
Preclinical studies of Notch inhibition with GSI in serous
ovarian cancer: in vivo models
Limited studies have investigated Notch inhibition in vivo
for the treatment of ovarian cancer. Using in vitro and
in vivo ovarian cancer models, McAuliffe and colleagues
have investigated both the anti-tumor efficacy of GSI-1 as a
single agent and in combination with cisplatin, and the ef-
fects of these treatments on ovarian CSC sub-populations.
These investigators observed a reduction in cell viability fol-
lowing GSI treatment and a synergistic response to com-
bined GSI and cisplatin therapy in established cell lines and
cultured cells derived from ascites samples of platinum re-
sistant and platinum sensitive patients. Sensitivity to GSI
was found to correlate with Notch3 protein levels, as
assessed by Western blotting. siRNA-mediated knockdown
of Notch3 increased sensitivity to cisplatin in PA-1 and
OVCAR3 cell lines and had no effect in SKOV3 cells which
do not express detectable levels of Notch3. The described
synergy of GSI and cisplatin was confirmed in vivo,u s i n g
xenografts derived from these established cell lines. In
addition, in vitro treatment with GSI or GSI +cisplatin de-
creased the side population and in vivo GSI therapy re-
duced both the side population and mRNA levels of the
CSC markers CD44 and ALDH1, suggesting GSI is effective
at eliminating CSCs [124]. The in vivo effect of single agent
GSI or GSI in combination with standard chemotherapy in
a patient derived xenograft (PDX) model was explored by
our group using cohorts of mice harboring PDX tumors de-
rived from either clinically platinum sensitive or clinically
platinum resistant primary ovarian serous tumors. Three of
four platinum sensitive tumors and one of three platinum
resistant tumors showed a decrease in tumor growth fol-
lowing single agent GSI treatment. Moreover, combination
treatment with GSI and paclitaxel led to a markedly greater
reduction in tumor growth compared with paclitaxel alone
and GSI alone in all platinum resistant tumors. The com-
bination of GSI with paclitaxel and carboplatin was not
more effective than paclitaxel/carboplatin alone in platinum
sensitive tumors [125]. These findings highlight a potential
role for Notch pathway inhibition in addition to cytotoxic
therapy in the recurrent, platinum resistant setting in ser-
ous ovarian cancer.
Clinical studies of Notch inhibition with GSI in serous
ovarian cancer
To date, early clinical trials have provided little data re-
garding the efficacy of GSIs in ovarian cancer patients. A
recent phase I clinical trial using the GSI RO4929097 in
a range of advanced solid tumors reported prolonged
stable disease in three of nine ovarian cancer patients
[122]. In other phase I studies, no clinical benefit of
RO4929097 in combination with gemcitabine was found
in two of two ovarian cancer patients included in the
trial [119], and the GSI MK-0752 was clinically ineffect-
ive as single agent therapy in three of three ovarian tu-
mors [120]. Tables 1 and 2 highlight ongoing trials of
various GSIs. While the only phase II trial exclusively in
ovarian carcinoma assesses RO4929097 as a single agent,
many other disease sites are testing GSI in combination
with other biologics or cytotoxic chemotherapies. In the
reported trial literature, the most clinical benefit has
been observed in those trials that combine GSI with
other agents suggesting a supporting therapeutic role for
GSI. The fact that monotherapy has resulted in lower
published clinical benefit rates stems in part from phase
I trial designs that are powered to detect toxicity, not
efficacy. However, an additional contributing factor is
that durable tumor control from Notch inhibition re-
quires careful selection for tumors innately dependent
on Notch signaling for proliferation.
To date, no trials testing Notch pathway inhibition in
patients pre-selected based on alterations in the Notch
pathway have been reported. Significant pre-clinical
data, however, seem to support such stratification as a
promising approach. Future clinical studies will need to
employ clinical as well as scientific endpoints to under-
stand better the molecular characteristics of tumors that
respond to therapy. Without a clear biomarker, specific
biologic therapies such as GSI, are unlikely to become a
mainstay of therapy. In addition to biomarker discovery,
more trials investigating combination of GSI with con-
ventional cytotoxics, such as taxanes needs to be con-
ducted. Pre-clinical rationale exists for this combination
approach as tumor cell resistance to cytotoxics and
other biologic therapies, such as taxanes and anti-HER2
therapies, has been linked to heightened Notch signaling
[131,132]. Since Notch may be an important escape
pathway that reconstitutes the oncogenic potential of a
tumor cell, Notch inhibition may be a key adjunct to
conventional therapies known to be effective [133].
Other Notch inhibitors in serous ovarian cancer
In addition to targeting of gamma-secretase activity, al-
ternative methods of Notch pathway inhibition have
been studied in ovarian cancer. Inhibition of Jag1 using
siRNA constructs in the IGROV-AF1 cell line and the
taxane resistant SKOV3Trip2 cell lines resulted in a re-
duction of cell viability as well as sensitization to doce-
taxel in SKOV3Trip2 cells. The same cell lines were
used to generate intraperitoneal tumors in mice, and the
effects of targeting Jag1 in stromal and malignant cells
were evaluated by treatment of mice with either mouse
specific Jag1 siRNA, human specific Jag1 siRNA or both
siRNA constructs. Either siRNA alone reduced tumor
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Jag1 siRNAs showed a synergistic effect in tumors de-
rived from both cell lines. Combination treatment of
SKOV3Trip2-derived tumors with human and mouse
specific Jag1 siRNAs and docetaxel led to the highest
decrease in tumor weight, compared with the siRNAs
alone or docetaxel alone. Microvessel densities were
reduced after treatment with anti-murine Jag1 siRNA,
suggesting this therapy induced anti-angiogenic effects
[134]. Finally, the natural compounds xanthohumol and
withaferin A inhibited cell growth and induced apoptosis
and cell cycle arrest in ovarian cancer cell lines through
downregulation of Notch1 (withaferin A and xanthohu-
mol) and Notch3 (withaferin A) [135,136].
Conclusions
Considerable evidence supports an important oncogenic
role of Notch signaling in high-grade serous ovarian can-
cer. Perturbation in normal regulation of Notch1 and
Notch3 as well as Notch ligands, target genes and other
members of the Notch pathway has been described. The
many biological and clinical aspects of ovarian tumori-
genesis in which aberrant Notch signaling appears to be
involved include tumor initiation and progression, me-
tastasis, resistance to chemotherapy, CSC activity, angio-
genesis and EMT. Despite its functional complexity and
crosstalk with other signaling cascades, the Notch path-
way represents an attractive therapeutic target in ovarian
cancer. Pre-clinical analysis of Notch inhibition suggests
Notch targeting agents such as GSIs hold promise as po-
tential treatment strategies for ovarian cancer patients,
most notably in the setting of recurrence and chemoresis-
tance. In addition, combination regimens with conven-
tional cytotoxic therapy as well as other targeted therapies
warrant further investigation.
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